Form D · Biotechnology
Anelixis Therapeutics, Inc.
Cambridge, MA · CIK 0001704400
Offering snapshot reported May 17, 2019 · SEC filing
- Reported sold
- $1M Offering amount: $6M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Apr 30, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 17, 2019 | Initial | $1,000,000 | No comparison | 10 | SEC filing |
| Apr 25, 2018 | Initial | $2,574,131 | No comparison | 6 | SEC filing |
| Jun 20, 2017 | Initial | $4,289,395 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $100K
- Finders' fees
- $0
- Form D file number
- 021-339827
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Noble Capital Markets | 15768 |
Source: Form D, filed May 17, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kent Bransford | Director |
| Eric Craven | Director |
| James Heywood | Director |
| Maeve Mcnally | Executive |
| Maeve Mc Nally | Executive |
| Augie Nieto | Director |
| Walter Ogier | Director |
| Steven Perrin | Director, Executive |
| Theodore Reich | Director |
| Paul Sallaberry | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
300 Technology Square, Suite 400
Cambridge, MA, 02139
Cambridge, MA, 02139